岩舒复方苦参注射液联合TP方案治疗晩期非小细胞肺癌的疗效观察  

Clinical observation on efficacy of Yanshu injection combined with paclitaxel and cisplatin regimen in treatment of advanced non-small cell lung cancer

作　　者：汤伟忠[1] 顾根网 王国方[1] Tang Weizhong;Gu Genwang;Wang Guofang(Department of Oncology,Danyang Hospital of Traditional Chinese Medicine,Zhenjiang 212300,Jiangsu,China)

机构地区：[1]丹阳市中医院肿瘤科,江苏镇江212300

出　　处：《中国中西医结合急救杂志》2019年第2期227-229,共3页Chinese Journal of Integrated Traditional and Western Medicine in Intensive and Critical Care

摘　　要：目的观察岩舒复方苦参注射液联合紫杉醇+顺钳(TP)化疗方案治疗晚期非小细胞肺癌(NSCLC)的临床疗效。方法选择2014年5月至2018年6月丹阳市中医院肿瘤科收治的NSCLC患者162例,所有病例均经病理学或细胞学确诊。将患者按给药种类的不同分为两组,每组81例。西药治疗组单独采用TP方案治疗,3周为1个周期,连续治疗3个周期;中西医结合治疗组在西医TP化疗方案基础上同时联用岩舒复方苦参注射液,连续治疗2周。观察两组治疗后临床疗效和不良反应发生率。结果中西医结合治疗组总有效率明显高于西药治疗组[60.49%(49/81)比40.74%(33/81), P<0.05〕;中西医结合治疗组脱发、血小板减少、神经毒性、白细胞减少、恶心呕吐、胃肠反应等药物不良反应发生率较西药治疗对照组明显降低〔脱发 24.69%(20/81)比 60.49%(49/81),血小板减少 23.45%(19/81)比 40.74%(33/81),神经毒性 14.81%( 12/81)比 34.57%(28/81),白细胞减少 17.28%(14/81)比 62.96%(51/81),恶心呕吐 14.81%(12/81 ) tt 60.49%(49),胃肠道反应27.16%(22/81)比62.96%(51/81),均P<0.05〕。结论岩舒复方苦参注射液联合TP化疗方案治疗晚期NSCLC的临床疗效显著,值得临床推广应用。Objective To analyze the clinical efficacy of Yanshu compound sophora flavescens injection (Yanshu injection) combined with paclitaxel and cisplatin (TP) regimen in the treatment of advanced non-small cell lung cancer (NSCLC). Methods One hundred and sixty-two patients with NSCLC admitted to the Department of Oncology of Danyang Hospital of Traditional Chinese Medicine from May 2014 to June 2018 were enrolled, all of their definite diagnosis was based on pathological or cytological examinations, and they were divided into two groups by the administration type, 81 cases in each group. The western medicine treatment group (western group) was treated with TP regimen alone, 3 weeks constituting 1 therapeutic course, and 3 consecutive courses were treated;based on the treatment of western drug TP regimen, the integrated traditional Chinese and western medicine treatment group (combined group) was additionally and simultaneously given Yanshu injection for consecutive 2 weeks. After treatment, the clinical efficacy and incidence of adverse reactions of the two groups were observed. Results The total effective rate in the combined group was significantly higher than that in western group [60.49%(49/81) vs. 40.74%(33/81), P < 0.05];the incidences of adverse events: alopecia, thrombocytopenia, neurotoxicity, leukopenia, nausea and vomiting, and gastrointestinal reaction in the combined group were obviously lower than those in western group [alopecia: 24.69%(20/81) vs. 60.49%(49/81), thrombocytopenia: 23.45%(19/81) vs. 40.74%(33/81), neurotoxicity: 14.81%(12/81) vs. 34.57%(28/81), leukopenia: 17.28%(14/81) vs. 62.96%(51/81), nausea and vomiting: 14.81%(12/81) vs. 60.49%(49/81), gastrointestinal reaction: 27.16%(22/81) vs. 62.96%(51/81), all P < 0.05]. Conclusion Yanshu injection combined with TP regimen is obviously effective in the treatment of advanced NSCLC, thus it is worthy to be applied clinically.

关 键 词：晚期非小细胞肺癌 岩舒复方苦参注射液 紫杉醇+顺钳化疗方案 中西医结合疗法 

分 类 号：R286.0[医药卫生—中药学]